Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGN-2012 in Recurrent Respiratory Papillomatosis
NCT04724980Phase 2Active, not recruiting
- Sponsor
- Precigen
- Start
- Mar 2021
- Primary completion
- Jun 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of zopapogene imadenovec in recurrent respiratory papillomatosis (RRP), sponsored by Precigen. Started Mar 2021; status: active, not recruiting.
02
Drugs
zopapogene imadenovec
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT04724980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04724980.